WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] => all
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 5065
[post_author] => 4
[post_date] => 2026-09-01 14:03:32
[post_date_gmt] => 2026-09-01 18:03:32
[post_content] =>
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here
Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here
[post_title] => BioREACH: Translational Research Funding Opportunity
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => bioreach-translational-research-funding-opportunity
[to_ping] =>
[pinged] =>
[post_modified] => 2026-09-04 11:55:36
[post_modified_gmt] => 2026-09-04 15:55:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=5065
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3747
[post_author] => 4
[post_date] => 2021-04-07 19:08:28
[post_date_gmt] => 2021-04-07 19:08:28
[post_content] =>
Companies with an active NIH SBIR or STTR Phase I or Phase I Fast-Track award (grant or contract) within the past two years are eligible to receive a Technical and Business Assistance (TABA) Program Needs Assessment Report*
The TABA Needs Assessment Report provides a third party, unbiased assessment of your progress in 10 technical and business areas that are critical to success in the competitive healthcare marketplace including Target Market Attractiveness (Need/Size), Ability to Address Market Need, Regulatory Path and more. Learn more: https://sbir.nih.gov/support-for-awardees/taba-needs-assessment
*For companies with multiple awards, only one project will be considered for the program. Small businesses that have received TABA funding within their Phase I award are not eligible to participate.
[post_title] => SBIR/ATTR Awardees: Open Eligibility for Needs Assessment Report
[post_excerpt] => Companies with an active NIH SBIR or STTR Phase I or Phase I Fast-Track award (grant or contract) within the past two years are eligible to receive a Technical and Business Assistance (TABA) Program Needs Assessment Report.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sbir-attr-awardees-open-eligibility-for-needs-assessment-report
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-20 16:12:02
[post_modified_gmt] => 2021-09-20 16:12:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3747
[menu_order] => 49
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 2417
[post_author] => 3
[post_date] => 2016-10-07 13:15:28
[post_date_gmt] => 2016-10-07 13:15:28
[post_content] => Vitatex, a Stony Brook-based biotechnology company located in the Long Island High Technology Incubator, has announced that it was awarded an SBIR Phase I/II Fast Track contract in September 2015 from the National Cancer Institute (NCI) for its Vita-Cap™ CTC Capture and Preservation tubes. A modification to exercise the option for a two-year SBIR Phase II of the contract was executed on June 8, 2016.
Vitatex Inc. provides proprietary invasive circulating tumor cell (iCTC) enrichment technology and products to develop revolutionary cancer genetic and cell tests. These "liquid biopsies" focus on next generation sequencing (NGS) detection, gene expression profiling and flow cytometry and have recently been adopted by the clinical laboratory community to characterize cancer cells and/or their RNA/DNA in blood samples non-invasively and serially, and to acquire genetic alternations and drug resistance information, which have the potential to replace tests run on surgical biopsies.
Clinical metastasis of solid tumors is linked to blood-borne dissemination of viable tumor cells in the circulation and clinical instrumentation is now available to isolate, enumerate, culture, generate metastatic mouse models and perform molecular analyses on these circulating tumor cells (CTCs). However, CTCs are fragile and tend to degrade within a few days when collected in standard blood collection tubes.
"The functional CTC preparation tube is designed to collect, enrich and preserve the viability/functionality of cancer cells in blood all within a closed system" said Wen-Tien Chen, PhD., Chief Scientific Officer of Vitatex. "The goal is to define conditions of Vitatex CTC preparation tubes for capturing and preserving cancer cells in the blood of patients with breast, ovarian and other types for up to 96 hours of transit."
Specific terms of the contract were not disclosed.
[post_title] => Vitatex Awarded NCI Contract
[post_excerpt] => Stony Brook biotech company, Vitatex, has announced it was awarded an NCI Contract for Circulating Tumor Cell (CTC) Capture and Preservation Tubes.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => vitatex-awarded-nci-contract
[to_ping] =>
[pinged] =>
[post_modified] => 2016-12-06 15:12:47
[post_modified_gmt] => 2016-12-06 15:12:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2417
[menu_order] => 164
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 3800
[post_author] => 3
[post_date] => 2021-06-30 17:32:55
[post_date_gmt] => 2021-06-30 17:32:55
[post_content] =>
BLUE KNIGHT™, a joint initiative between Johnson & Johnson
Innovation – JLABS (‘JLABS’) and the Biomedical Advanced Research and
Development Authority (BARDA), offers emerging life science companies an
opportunity to join the JLABS incubator ecosystem with additional engagement
from BARDA. BLUE KNIGHT™ companies, selected for their mutual alignment to the
Johnson & Johnson Family of Companies’ and BARDA areas of interest, may
also have an opportunity to receive additional support, including fee
assistance and mentorship.
If you are looking to learn more about BLUE KNIGHT™, mutual areas of interest between the Johnson & Johnson Family of Companies and BARDA, and what the application process entails, join the Information Session and Fireside Chat on July 22, 2021 at 1:00pm ET. Register and learn more here:
https://forgethefuture.splashthat.com/tw
[post_title] => Forge the Future: Expanded Pathways for BLUE KNIGHT™ Collaboration
[post_excerpt] => Learn more about BLUE KNIGHT™, a joint initiative between JLABS and BARDA, at the Information Session and Fireside Chat on July 22, 2021 at 1:00pm ET.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => forge-the-future-expanded-pathways-for-blue-knight-collaboration
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-20 16:03:37
[post_modified_gmt] => 2021-09-20 16:03:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3800
[menu_order] => 41
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 5065
[post_author] => 4
[post_date] => 2026-09-01 14:03:32
[post_date_gmt] => 2026-09-01 18:03:32
[post_content] =>
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here
Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here
[post_title] => BioREACH: Translational Research Funding Opportunity
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => bioreach-translational-research-funding-opportunity
[to_ping] =>
[pinged] =>
[post_modified] => 2026-09-04 11:55:36
[post_modified_gmt] => 2026-09-04 15:55:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=5065
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 285
[max_num_pages] => 95
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
[query_cache_key:WP_Query:private] =>
)
